PL428782A1 - Nowe związki wankomycyny i TP10, sposób ich otrzymywania, kompozycja oraz zastosowanie w leczeniu przeciwbakteryjnym - Google Patents

Nowe związki wankomycyny i TP10, sposób ich otrzymywania, kompozycja oraz zastosowanie w leczeniu przeciwbakteryjnym

Info

Publication number
PL428782A1
PL428782A1 PL428782A PL42878219A PL428782A1 PL 428782 A1 PL428782 A1 PL 428782A1 PL 428782 A PL428782 A PL 428782A PL 42878219 A PL42878219 A PL 42878219A PL 428782 A1 PL428782 A1 PL 428782A1
Authority
PL
Poland
Prior art keywords
preparation
application
compounds
composition
antibacterial treatment
Prior art date
Application number
PL428782A
Other languages
English (en)
Other versions
PL242410B1 (pl
Inventor
Izabela RUSIECKA
Ivan KOCIĆ
Jarosław RUCZYŃSKI
Piotr REKOWSKI
Original Assignee
Gdański Uniwersytet Medyczny
Uniwersytet Gdański
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdański Uniwersytet Medyczny, Uniwersytet Gdański filed Critical Gdański Uniwersytet Medyczny
Priority to PL428782A priority Critical patent/PL242410B1/pl
Priority to PCT/PL2020/000010 priority patent/WO2020159389A1/en
Publication of PL428782A1 publication Critical patent/PL428782A1/pl
Publication of PL242410B1 publication Critical patent/PL242410B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nowy związek o wzorze ogólnym: gdzie: X - oznacza PEG3; PEG4; Ala-PEG4; TP10 - oznacza X-AGYLLGK(X)INLKALAALAKKIL-X-NH2. Ponadto, zgłoszenie obejmuje też sposób otrzymywania przedmiotowych związków, ich zastosowanie oraz zawierającą je kompozycję farmaceutyczną.
PL428782A 2019-01-31 2019-01-31 Sposób otrzymywania koniugatów wankomycyny i TP10, koniugaty otrzymane tym sposobem oraz ich zastosowanie w leczeniu przeciwbakteryjnym PL242410B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL428782A PL242410B1 (pl) 2019-01-31 2019-01-31 Sposób otrzymywania koniugatów wankomycyny i TP10, koniugaty otrzymane tym sposobem oraz ich zastosowanie w leczeniu przeciwbakteryjnym
PCT/PL2020/000010 WO2020159389A1 (en) 2019-01-31 2020-01-29 Compounds of vancomycin and tp10, methods of their preparation, composition and use in antibacterial treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL428782A PL242410B1 (pl) 2019-01-31 2019-01-31 Sposób otrzymywania koniugatów wankomycyny i TP10, koniugaty otrzymane tym sposobem oraz ich zastosowanie w leczeniu przeciwbakteryjnym

Publications (2)

Publication Number Publication Date
PL428782A1 true PL428782A1 (pl) 2020-08-10
PL242410B1 PL242410B1 (pl) 2023-02-20

Family

ID=70050180

Family Applications (1)

Application Number Title Priority Date Filing Date
PL428782A PL242410B1 (pl) 2019-01-31 2019-01-31 Sposób otrzymywania koniugatów wankomycyny i TP10, koniugaty otrzymane tym sposobem oraz ich zastosowanie w leczeniu przeciwbakteryjnym

Country Status (2)

Country Link
PL (1) PL242410B1 (pl)
WO (1) WO2020159389A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023225904A1 (zh) * 2022-05-25 2023-11-30 深圳先进技术研究院 一种用于检测颅内葡萄球菌感染的试剂底物以及试剂盒的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2688580A4 (en) * 2011-03-24 2015-03-25 Seachaid Pharmaceuticals Inc DERIVATIVES OF VANCOMYCIN
WO2015022335A1 (en) * 2013-08-12 2015-02-19 Katholieke Universiteit Leuven Vancomycin analogs
EP3158992A1 (en) * 2015-10-21 2017-04-26 Universität Heidelberg Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
US11634448B2 (en) * 2016-06-15 2023-04-25 The General Hospital Corporation Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions

Also Published As

Publication number Publication date
PL242410B1 (pl) 2023-02-20
WO2020159389A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
GEP20237506B (en) Pcsk9 antagonist compounds
CY1121729T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων
MY209310A (en) Sting agonistic compound
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
MX2021006969A (es) Ligante peptidico.
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
MX2018014813A (es) Composiciones antibacterianas.
WO2016068580A3 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
MX394624B (es) Inhibidores selectivos hdac6, métodos de preparación y aplicación de los mismos.
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PH12019502509A1 (en) Compounds and methods for treating bacterial infections
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
EA201491982A1 (ru) Антибактериальные хинолиновые производные
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
PL428782A1 (pl) Nowe związki wankomycyny i TP10, sposób ich otrzymywania, kompozycja oraz zastosowanie w leczeniu przeciwbakteryjnym
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
PH12021550323A1 (en) Dendrimer formulations
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
NZ719215A (en) Pharmaceutical compositions comprising antibacterial agents